Elusive Cancer Gene RAS Targeted by Combinatorial Therapy Approach

Researchers have made a significant breakthrough in targeting the elusive cancer gene RAS, which has long been a challenge in cancer treatment. According to a study published in Clinical Cancer Research, recent technological advances and discoveries have greatly expanded our knowledge of the biology of oncogenic Ras and its role in cancer. The study highlights the dependence of RAS-mutant cells on nononcogenic signaling pathways and identifies potential vulnerabilities that can be exploited for therapeutic intervention.

Key Takeaways:

• The RAS gene remains the most elusive to target among the genes mutated in cancer, despite significant research efforts.
• Recent advances in technology have greatly expanded our understanding of the biology of oncogenic Ras and its role in cancer.
• RAS-mutant cells are dependent on nononcogenic signaling pathways, including the DNA damage response, as a means of adaptation to intracellular stresses.
• A number of studies have identified the molecular pathways that mediate this process, including signaling from wild-type Ras isoforms, ATR/Chk1, and DNA damage repair pathways.
• Combinatorial therapy approaches, such as using farnesyltransferase inhibitors, Chk1 inhibitors, or small-molecule targeting DNA damage repair, have been identified as potential strategies for targeting the dependence of RAS cancers on the DNA damage response.
• The study highlights the importance of further research in this area to develop effective therapies for RAS-mutant cancers.
• E. Grabocka, C. Commisso, and D. Bar-Sagi are among the researchers who contributed to this study, which has significant implications for the development of new cancer therapies.

Statistics:

• 1243-1247: The page numbers of the study published in Clinical Cancer Research, 2015;21(6).
• 2015: The year the study was published.
• Cancer: The type of disease being targeted by the RAS gene therapy research.
• Oncology: The field of medicine that focuses on the diagnosis and treatment of cancer.
• DNA Damage: A key aspect of cancer biology that is being targeted by RAS gene therapy research.
• Proteomics: A field of study that has contributed to the understanding of the biology of oncogenic Ras.
• DNA Research: The focus of the study published in Clinical Cancer Research.
• 15th Floor, 615 Chestnut St: The address of the American Association for Cancer Research.

Sources:

• Molecular Pathways: Targeting the Dependence of Mutant RAS Cancers on the DNA Damage Response. Clinical Cancer Research, 2015;21(6):1243-1247.
• Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA.
• American Association for Cancer Research - www.aacr.com
• Clinical Cancer Research - clincancerres.aacrjournals.org/
• E. Grabocka, New York University, Sch Med, Dept. of Biochem & Mol Pharmacol, New York, NY, United States.
• C. Commisso and D. Bar-Sagi, DNA Research.